Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2005-3-29
pubmed:abstractText
Human immunodeficiency virus type 1 (HIV-1) mutates to escape immune selection pressure, but there is little evidence of selection mediated through HLA-A2, the dominant class I allele in persons infected with clade B virus. Moreover, HLA-A2-restricted responses are largely absent in the acute phase of infection as the viral load is being reduced, suggesting that circulating viruses may lack immunodominant epitopes targeted through HLA-A2. Here we demonstrate an A2-restricted epitope within Vpr (Vpr59-67) that is targeted by acute-phase HIV-1-specific CD8+ T cells, but only in a subset of persons expressing HLA-A2. Individuals in the acute stage of infection with viruses containing the most common current sequence within this epitope (consensus sequence) were unable to mount epitope-specific T-cell responses, whereas subjects infected with the less frequent I60L variant all developed these responses. The I60L variant epitope was a stronger binder to HLA-A2 and was recognized by epitope-specific T cells at lower peptide concentrations than the consensus sequence epitope. These data demonstrate that HLA-A2 is capable of contributing to the acute-phase cytotoxic T-lymphocyte response in infected subjects, but that most currently circulating viruses lack a dominant immunogenic epitope presented by this allele, and suggest that immunodominant epitopes restricted by common HLA alleles may be lost as the epidemic matures.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-10562305, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-10846155, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-11148221, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-11148222, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-11152503, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-11157057, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-11376327, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-11460164, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-11543903, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-11704282, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-11981371, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-11984594, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-12029119, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-12029127, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-12089434, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-12163596, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-12459786, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-12743293, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-14770175, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-14966520, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-14991039, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-15194783, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-15265949, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-15286729, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-1721107, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-3496541, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-9018240, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-9018241, http://linkedlifedata.com/resource/pubmed/commentcorrection/15795285-9050875
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0022-538X
pubmed:author
pubmed:issnType
Print
pubmed:volume
79
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5000-5
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design.
More...